Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Multivariate logistic regression analysis of established and experimental factors for predicting a pathological complete response, irrespective of study treatment: clinical response after two cycles excluded from second analysis

From: Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

  First analysis Second analysis
  Odds ratio 95% CI p Value Odds ratio 95% CI p Value
Menopausal status 1.63 0.44 to 6.05 0.467 1.89 0.55 to 6.51 0.312
Tumour size 1.75 0.46 to 6.68 0.411 1.80 0.51 to 6.40 0.363
Clinical nodal status 5.48 1.24 to 24.16 0.025 5.44 1.35 to 21.87 0.017
Grade 0.21 0.03 to 1.33 0.098 0.16 0.03 to 0.91 0.039
Clinical response after two cycles 3.68 0.90 to 15.03 0.069 - - -
Hormonal receptor 27.00 2.21 to 330.57 0.010 7.83 1.24 to 49.42 0.029
Ki-67 0.75 0.16 to 3.56 0.716 0.78 0.18 to 3.39 0.740
HER2 4.09 0.70 to 24.08 0.119 3.66 0.69 to 19.30 0.126
p53 4.11 0.73 to 23.01 0.108 2.55 0.56 to 11.66 0.227
bcl-2 3.75 0.35 to 39.54 0.272 4.98 0.53 to 46.95 0.161
  1. HER2, human epidermal growth factor receptor 2.